Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

Clinical Trial ID NCT01108445

Rank	Title	Journal	Year	PubWeight™‹?›
1	A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.	Eur Urol	2012	2.77
2	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	Lancet Oncol	2016	2.30
3	Targeted therapeutic strategies for the management of renal cell carcinoma.	Curr Opin Oncol	2012	1.00
4	Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.	Front Oncol	2015	0.83
5	Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.	BMC Urol	2013	0.83
6	Targeting the mTOR pathway in Chromophobe Kidney Cancer.	J Cancer	2012	0.82
7	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.	Clin Genitourin Cancer	2014	0.76
8	Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma.	Open Access J Urol	2011	0.75
9	Therapeutic challenges in advanced renal cell carcinoma.	Clin Pract (Lond)	2013	0.75
10	Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.	Target Oncol	2011	0.75
11	Open clinical uro-oncology trials in Canada.	Can J Urol	2012	0.75